Christos Vaklavas

11PUBLICATIONS
78CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical devicesCancer therapy (excl. chemotherapy and radiation therapy)Exercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Apr 03, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.

Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter

|Sep 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Rebecca A Shatsky, Meghna S Trivedi, Christina Yau

|Sep 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Katia Khoury, Jane L Meisel, Christina Yau

|Jul 29, 2024
TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer.

Christos Vaklavas, Cindy B Matsen, Zhengtao Chu

|Feb 03, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany

Pageof 2

Frequent Collaborators

3 joint publications

Alana L Welm

2 joint publications

Roisin M Connolly

2 joint publications

Chiung-Yu Huang

2 joint publications

Vandana G Abramson